2024-09-04 - Analysis Report
## Lilly (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Company is a global pharmaceutical company known for developing and manufacturing innovative medicines in various therapeutic areas.

**Performance Analysis:**

1. **Performance vs. S&P 500:** 
    * **Cumulative Return:** LLY: 571.94%, VOO: 89.66%
    * **Return Difference:** 482.28%
    * **Relative Divergence:** 100.0% (LLY has outperformed VOO by a significant margin, exceeding its performance by a substantial amount).

2. **Recent Price Movement:**
    * **Closing Price:** $960.02
    * **5-Day Moving Average:** $950.83
    * **20-Day Moving Average:** $907.01
    * **60-Day Moving Average:** $888.73 
    * **Analysis:** LLY is currently trading above its 5, 20, and 60-day moving averages, indicating a potential uptrend.

3. **Technical Indicators:**
    * **RSI:** 78.82 (Overbought)
    * **PPO:** 0.36 (Positive, suggesting potential uptrend)
    * **Delta_Previous_Relative_Divergence:** 18.98 (Positive, indicating a recent short-term upward trend).
    * **Expected_Return:** 0.0% (This represents the maximum 5-year expected return on a current investment, based on historical data).

4. **Recent Earnings and Outlook:**
    * **Latest Earnings (2024-08-08):** EPS of $3.29 (Exceeding estimates), Revenue of $11.30 Billion. 
    * **Analysis:**  Lilly has consistently delivered strong earnings in recent quarters, exceeding analysts' expectations. The company's robust revenue growth demonstrates the success of its pharmaceutical portfolio and strong market demand for its products.

**Summary:**

Lilly (LLY) has exhibited strong performance, significantly outperforming the S&P 500.  Recent price movements suggest potential continued upward momentum, supported by its technical indicators. The company's latest earnings report highlights its exceptional performance and a promising outlook for the future. However, it's important to note that the RSI suggests the stock is currently overbought, potentially indicating a near-term correction.  Overall, LLY presents a compelling investment opportunity for those seeking exposure to the pharmaceutical sector and a potential growth play. 

**Disclaimer:** This is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified professional.